Compass Therapeutics Q3 net loss widens 90% to $27.2 million

• Compass Therapeutics’ third-quarter 2026 net loss widened 90% year over year to $27.2 million.
• Research and development expenses rose 72% to $22 million, primarily driven by tovecimig manufacturing costs.
• General and administrative expenses more than doubled to $6.8 million, primarily driven by higher stock-based compensation and pre-commercialization expenses.
• Cash and marketable securities totaled $163 million at September 30, 2026, with operations expected to be funded into 2028.
• Tovecimig BLA preparations continue, although the FDA recommended an additional study demonstrating a survival benefit before submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-007256), on November 09, 2026, and is solely responsible for the information contained therein.